Clotting factor concentrates (CFC) or bypassing agents (BPA)

BIOLOGICAL3 trials

Sponsors

Sanofi

Conditions

HemophiliaHemophilia A

Phase 3

A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia

Active, not recruitingNCT05662319

SanofiHemophilia

Start: 2023-02-01End: 2029-01-25Updated: 2026-02-04

A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B

RecruitingNCT07285460

SanofiHemophilia

Start: 2025-12-18End: 2031-12-30Target: 85Updated: 2026-08-17

Phase 4

A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab

RecruitingNCT06145373

SanofiHemophilia A

Start: 2024-03-01End: 2030-01-30Target: 20Updated: 2026-06-02

Related Papers

Evaluating the safety and tolerability of switching from emicizumab to fitusiran prophylaxis in adult males with severe hemophilia A, with or without inhibitors: SWITCH study, a trial in progress

Blood2025-11-03

Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study

Blood2025-03-0720 citations

Strategies for Increasing Racial and Ethnic Diversity in Hemophilia Clinical Trials and Their Outcomes

Blood2024-11-05

Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial

Blood2024-03-0733 citations